论文部分内容阅读
近年来心钠素(ANP)的临床研究正以惊人的速度向前发展,尤其是心功能不全时血浆ANP的变化和可能的治疗意义正日益引起重视。大量的资料表明,充血性心衰的患者血浆ANP水平通常比正常对照组高2～10倍,并认为是由于心衰时心排出量减少,心室舒张末压升高,导致心房容量和压力升高通过心房壁机械感受器而使心房肌细胞的ANP释放增加的结果。原发性扩张型心肌病(DCM)是以心室收缩功能不全所致的泵功能障碍为特征,起病缓慢,临床上有心脏扩大、充血性心衰、心律失常及栓塞的表现,本文综述其ANP变化的研究进展。 1血浆ANP水平的变化 1.1实验性DCM血浆ANP水平的变化;Edwards等测得DCM仓鼠(BIO 14.6)的
In recent years, clinical research of atrial natriuretic peptide (ANP) is progressing at an alarming rate. Especially, the changes of plasma ANP and the possible therapeutic significance of cardiac insufficiency are attracting more and more attention. A large number of data show that plasma ANP levels in patients with congestive heart failure usually 2 to 10 times higher than the normal control group, and that is due to cardiac output decreased cardiac output, increased ventricular end-diastolic pressure, leading to atrial volume and pressure rise High through the atrial wall mechanoreceptors and atrial myocyte ANP release results. Primary dilated cardiomyopathy (DCM) is characterized by pump dysfunction caused by ventricular systolic dysfunction, slow onset, clinical manifestations of cardiac enlargement, congestive heart failure, arrhythmia and embolism. This article reviews its Research Progress of ANP Changes. 1 changes in plasma ANP levels 1.1 changes in experimental DCM plasma ANP levels; Edwards et al measured DCM hamster (BIO 14.6)